Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Coal tar soln 25% in Betamethasone valerate 0.1% ointment
1304000F0AAFMFM
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar soln 3% / Salicylic acid 3% in Gen Unguentum M crm
1305020C0AAGKGK
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 3% / Salicylic acid 3% in White soft paraffin
1305020C0AAFHFH
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 4% / Salicylic acid 2% in White soft paraffin
1305020C0AAHGHG
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 5% / Clobetasone 0.05% crm 15% in Aqueous crm
1304000H0AACJCJ
|
Clobetasone butyrate (Topical) | Clobetasone butyrate | Skin | No data available |
|
Coal tar soln 5% / Salic acid 5% in Betameth val 0.025% oint
1305020I0AAAJAJ
|
Coal tar and corticosteroids | Coal tar and corticosteroid preparations | Skin | No data available |
|
Coal tar soln 5% / Salicylic acid 2% in Gen Unguentum M crm
1305020C0AAGDGD
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 5% /Salic acid 10% in Betameth val 0.025% oint
1305020I0AAAIAI
|
Coal tar and corticosteroids | Coal tar and corticosteroid preparations | Skin | No data available |
|
Coal tar soln 6% / Salicylic acid 6% in Gen Unguentum M crm
1305020C0AAGSGS
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 6%/Salicylic acid 2.5% in White soft paraffin
1305020C0AAFRFR
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar soln 7% / Salicylic acid 5% in Gen Unguentum M crm
1305020C0AAGMGM
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution
1305020C0AAAMAM
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 0.5% in White soft paraffin
1305020C0AAGZGZ
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 1% in Aqueous cream
1305020C0AAEVEV
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 10% / Salicylic acid 2% in Aqueous cream
1305020C0AAFYFY
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 10% in Aqueous cream
1305020C0AAEWEW
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 10% in Betamethasone valerate 0.025% cream
1304000F0AAEZEZ
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar solution 10% in Betamethasone valerate 0.1% cream
1304000F0AAERER
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar solution 10% in Clobetasol 0.05% cream
1304000G0AADDDD
|
Clobetasol propionate | Clobetasol propionate | Skin | No data available |
|
Coal tar solution 10% in Clobetasol 0.05% ointment
1304000G0AACYCY
|
Clobetasol propionate | Clobetasol propionate | Skin | No data available |
|
Coal tar solution 10% in Emulsifying ointment
1305020C0AAERER
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 10% in White soft paraffin
1305020C0AAEQEQ
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 12.5% in Emulsifying ointment
1305020C0AAECEC
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 12% in Yellow soft paraffin
1305020C0AAEHEH
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 15% in Aqueous cream
1305020C0AAEDED
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.